Iris Tavor
Algemeen Adviseur bij ENLIVEX THERAPEUTICS LTD.
Profiel
Iris Tavor is currently a Senior Director of Regulatory and Quality Affairs at Enlivex Therapeutics Ltd.
She previously worked as the Head of Quality and Regulatory Affairs at Pluristem Ltd.
Actieve functies van Iris Tavor
| Bedrijven | Functie | Begin |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Algemeen Adviseur | - |
Eerdere bekende functies van Iris Tavor
| Bedrijven | Functie | Einde |
|---|---|---|
Pluristem Ltd.
 Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Algemeen Adviseur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
